The ACTR1B Knockout 143B Polyclonal Cells product offers a CRISPR/Cas9-edited polyclonal population of 143B osteosarcoma cells with targeted disruption of the ACTR1B gene. ACTR1B encodes a core subunit of the dynactin Arp1 mini-filament, essential for dynein-mediated transport. The polyclonal format represents a heterogeneous pool of edited cells, providing a robust loss-of-function model without clonal selection. This population is ideal for studying dynactin-dependent processes in a bone cancer context.
The host 143B cell line is a widely used human osteosarcoma model derived from a primary tumor. Known for its highly metastatic behavior, 143B cells serve as a standard system for investigating bone cancer biology, tumor progression, and metastatic dissemination. The line’s aggressive phenotype makes it particularly suitable for evaluating genes involved in cell migration and invasion.
ACTR1B functions as a critical structural element of the dynactin complex, coupling cytoplasmic dynein to cargoes for minus-end-directed microtubule transport. Within the Arp1 filament, ACTR1B interacts with DCTN1, DCTN2, ACTR1A, and CAPZA, linking the motor to vesicles, mitochondria, and lysosomes. Upstream cell cycle kinases CDK1 and PLK1 regulate dynactin during mitosis, while downstream cargo recognition affects mitotic spindle organization and checkpoint signaling. Consequently, ACTR1B disruption impairs organelle positioning, autophagosome trafficking, and spindle assembly.
In the 143B osteosarcoma context, ACTR1B knockout provides a powerful tool to dissect contributions of dynein-dynactin to cancer cell behavior. Osteosarcoma cells depend on efficient intracellular transport and mitotic fidelity, and loss of ACTR1B is expected to impair directed cell migration??a key determinant of metastatic spread. This model enables researchers to connect dynactin complex integrity with osteosarcoma aggressiveness and to explore ACTR1B as a potential vulnerability in metastatic bone cancer.
This polyclonal knockout population enables a variety of assays, including immunofluorescence microscopy for dynactin localization, live-cell imaging of organelle transport, wound healing migration, and co-immunoprecipitation of dynactin components. Western blotting confirms ACTR1B protein loss, while flow cytometry and apoptosis assays assess cell cycle and survival effects. Applications range from mechanistic studies of mitosis and dynein cargo adaptor identification to therapeutic target validation in osteosarcoma. For further technical information or to place an order, please contact Ascent Research.
